Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

DCx will gain rights to technology, targets, and preclinical programs from Repare along with lab space and staff in Montreal.

The companies will analyze RNA sequencing data from Scipher to identify biomarkers for patient stratification and drug development.